Abstract
### Learning Point for Physicians This case illustrates the difficulties in treating hypercalcemia caused by parathyroid carcinoma. However, there are various choices of treatment and in recalcitrant cases, denosumab should be considered as a therapeutic option. It is important to know the vitamin D status of the patient and to monitor for hypocalcemia post treatment. Parathyroid carcinoma is rare; accounting for ∼1% of all the causes of primary hyperparathyroidism.1 When the tumor is no longer amenable for surgery, medical therapy to control the hypercalcemia becomes the main focus of management. Unfortunately, parathyroid carcinoma mediated hypercalcemia is often severe and more resistant to medical therapy. We report a case of parathyroid carcinoma with refractory hypercalcemia treated with denosumab. A 26-year-old lady with recurrent parathyroid carcinoma initially presented in April 2012 with symptoms of hypercalcemia, a serum calcium of 4.0 mmol/l with …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
